December 3, 2012
Long-Acting Erythropoiesis Stimulating Agent NESP® INJECTION PLASTIC SYRINGE with Unified Injection Volume Released for Sale
Tokyo, Japan, December 3, 2012---Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151, President and CEO: Nobuo Hanai, "Kyowa Hakko Kirin") announced today that it has released long-acting erythropoiesis stimulating agent NESP® INJECTION PLASTIC SYRINGE (NESP®) products for sale with unified injection volume standards.
Since NESP® was released for sale as a long-acting erythropoiesis stimulating agent in July 2007, it has been highly evaluated for exhibiting excellent clinical efficacy against renal anemia in all phases of kidney disease from the conservative phase to the dialysis phase and is now used by many medical institutions.
Injection volume for NESP® has been unified to 0.5 mL to make preparations suitable for both intravenous and subcutaneous administration. Kyowa Hakko Kirin hopes that this will allow it to provide therapeutic agents leading to even greater satisfaction.
Kyowa Hakko Kirin will contribute to the treatment of more kidney diseases by strengthening its products in this area, a core disease field.